CLINICAL CHARACTERISTICS, BIOMARKER USE, AND PATIENT-REPORTED BURDEN IN PLATINUM-RESISTANT OVARIAN CANCER (PROC) IN CLINICAL PRACTICE
Author(s)
Vijay N. Joish, PhD1, Sam Darbha, PhD2, Alex Rider, BSc3, Emily Yang Liu, PharmD, RPh1, Neeraj N. Iyer, PhD1, Tongsheng Wang, MS1, Steve Liang, PhD1;
1Genmab, Princeton, NJ, USA, 2Health Economics and Outcomes Research, Datawave Solutions Corp, Cranbury, NJ, USA, 3Adelphi Real World, Bollington, United Kingdom
1Genmab, Princeton, NJ, USA, 2Health Economics and Outcomes Research, Datawave Solutions Corp, Cranbury, NJ, USA, 3Adelphi Real World, Bollington, United Kingdom
OBJECTIVES: PROC is characterized by a poor prognosis and a limited range of effective therapeutic options for patients. We aim to describe real-world clinical characteristics, supportive care requirements, biomarker testing practices, treatment patterns, and patient-reported outcomes (PROs) among US patients with PROC using integrated physician- and patient-level data.
METHODS: This retrospective, cross-sectional analysis utilized data from the Adelphi Real World Ovarian Cancer Disease Specific Programme. Physicians completed forms capturing demographic, clinical, symptom, biomarker, and treatment data for consulting patients with PROC. Patients completed validated PRO instruments: EORTC QLQ-C30, EORTC QLQ-OV28, and Work Productivity and Activity Impairment (WPAI) questionnaires. Descriptive analyses summarized continuous variables as means (SD) and categorical variables as n (%).
RESULTS: A total of 104 patients with PROC were included (mean age 62.1 years; 56.7% White, 34.6% Black). ECOG status was 0-1 for 74% and 2 among 26%. Abnormal CA-125 levels were noted in 65.4%, and 40.4% had palpable disease. Frequent physician-reported symptoms included fatigue (38.5%), nausea (27.9%), appetite loss (26.0%), and weight loss (22.1%). Over half (51.9%) required additional daily support, primarily from a partner/spouse (34.6%), with common ADL assistance in housecleaning (19.2%) and shopping/meal preparation (16.3%). Biomarker testing was most frequent for CA-125 (68.3%), while predictive testing remained low: HER2 (26.9%), PD-L1 (24.0%), MSI (16.3%), and FRα (~12%). Treatment patterns showed 48.5% received NCCN guideline-concordant chemotherapy; 17.2%, biomarker- or histology-driven therapies (eg, PARP inhibitors); and 34.3%, alternative regimens. Among 23 completed PROs, mean QLQ-C30 scores indicated moderate functional impairment (social, 58.0; role, 63.8) and clinically meaningful symptom burden (fatigue, 42.0; insomnia, 40.6). WPAI responses (n=21) revealed 33% employment, with most reporting productivity loss, and 57% moderate and 19% severe activity impairment.
CONCLUSIONS: Patients with PROC experienced high symptom burden, caregiver dependence, and heterogeneous biomarker testing patterns, highlighting substantial unmet clinical needs in real-world practice settings.
METHODS: This retrospective, cross-sectional analysis utilized data from the Adelphi Real World Ovarian Cancer Disease Specific Programme. Physicians completed forms capturing demographic, clinical, symptom, biomarker, and treatment data for consulting patients with PROC. Patients completed validated PRO instruments: EORTC QLQ-C30, EORTC QLQ-OV28, and Work Productivity and Activity Impairment (WPAI) questionnaires. Descriptive analyses summarized continuous variables as means (SD) and categorical variables as n (%).
RESULTS: A total of 104 patients with PROC were included (mean age 62.1 years; 56.7% White, 34.6% Black). ECOG status was 0-1 for 74% and 2 among 26%. Abnormal CA-125 levels were noted in 65.4%, and 40.4% had palpable disease. Frequent physician-reported symptoms included fatigue (38.5%), nausea (27.9%), appetite loss (26.0%), and weight loss (22.1%). Over half (51.9%) required additional daily support, primarily from a partner/spouse (34.6%), with common ADL assistance in housecleaning (19.2%) and shopping/meal preparation (16.3%). Biomarker testing was most frequent for CA-125 (68.3%), while predictive testing remained low: HER2 (26.9%), PD-L1 (24.0%), MSI (16.3%), and FRα (~12%). Treatment patterns showed 48.5% received NCCN guideline-concordant chemotherapy; 17.2%, biomarker- or histology-driven therapies (eg, PARP inhibitors); and 34.3%, alternative regimens. Among 23 completed PROs, mean QLQ-C30 scores indicated moderate functional impairment (social, 58.0; role, 63.8) and clinically meaningful symptom burden (fatigue, 42.0; insomnia, 40.6). WPAI responses (n=21) revealed 33% employment, with most reporting productivity loss, and 57% moderate and 19% severe activity impairment.
CONCLUSIONS: Patients with PROC experienced high symptom burden, caregiver dependence, and heterogeneous biomarker testing patterns, highlighting substantial unmet clinical needs in real-world practice settings.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR59
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology